This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.
Age ≥ 18 years old;
Confirmed diagnosis of lower-risk MDS;
Platelet ≤ 30×109/L, or < 50×109/L and accompanied by bleeding events;
Baseline liver and kidney functions <2 ULN;
History of leukemia or stem cell transplantation, treatment-related MDS or malignant tumors;
With splenomegaly or myelofibrosis;
Infections or bleeding that cannot be controlled by standard treatment;
Any concurrent malignant tumors within the past 5 years, or basal cell carcinoma of the skin at the local site;